SEC Form 4 · accession 0001140361-19-004430

Asterias Biotherapeutics, Inc. · AST

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — CFO and General Counsel

Period of report

Mar 1, 2019

Accepted (ET)

Mar 5, 2019 · 4:30 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001572552

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Mar 1, 2019	A	145,263	$0.00	A	299,980	D
Common Stock	Mar 1, 2019	F	44,471	$0.95	D	255,509	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Options^F3	$1.95	holding	—	—	—	—	Mar 14, 2028	Common Stock	150,000	150,000	D
Stock Option^F4	$2.91	holding	—	—	—	—	Jul 17, 2026	Common Stock	380,000	380,000	D

F1The shares reported herein were awarded to the Reporting Person by the Issuer's Board of Directors upon recommendation by the Compensation Committee, in connection with the Company's 2018 bonus payment to the Reporting Person, in lieu of cash payment to the Reporting Person.
F2Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the grant of shares reported herein.
F3Subject to Mr. Chavez's continued employment with the Company, 25% of the granted stock options vest on the first anniversary of the grant date, and the remaining 75% of the stock options in equal monthly installments over 36 months commencing after the first anniversary of the grant date. The grant date of these options was March 14, 2018. The stock options are exercisable upon vesting.
F4Subject to Mr. Chavez's continued employment with the Company, 25% of the granted stock options vest on the first anniversary of the grant date, and the remaining 75% of the stock options in equal monthly installments over 36 months commencing after the first anniversary of the grant date. The grant date of these options was July 18, 2016. The stock options are exercisable upon vesting.